21 Oct 2026

Clascoterone for Hair Loss: Evidence, Safety, and FDA Status

Explore the evidence, safety, and FDA status of clascoterone for hair loss, including how Winlevi differs from the scalp treatment in trials. Learn more.

Share

Clascoterone is an investigational topical androgen-receptor blocker for androgenetic alopecia, commonly called male or female pattern hair loss. It is not FDA-approved for hair loss in the United States, and Winlevi—the approved acne product containing clascoterone—is not interchangeable with the investigational scalp formulation.

TL;DR

Clascoterone is a topical androgen-receptor blocker being studied for male pattern hair loss. It is not currently FDA-approved for that use. Winlevi contains clascoterone, but its 1% acne cream is not interchangeable with the investigational 5% scalp solution. We view the early findings as encouraging, not conclusive. People with active thinning should seek a diagnosis rather than delay established care or repurpose an acne product.

The main appeal of clascoterone for hair loss is its proposed local action. Instead of lowering DHT throughout the body, it aims to block androgen signaling at receptors in treated scalp skin. That could make it useful for some people if larger, published studies confirm meaningful and durable benefit.

Table of Contents

Clascoterone for hair loss: the short answer

Clascoterone for hair loss: the short answer

Clascoterone is a topical androgen-receptor antagonist studied for androgen-related conditions. For hair loss, its appeal lies in potentially blocking androgen signaling within treated scalp skin rather than reducing dihydrotestosterone, or DHT, throughout the body.

Last reviewed: October 20, 2026. In the United States, clascoterone is approved as Winlevi 1% cream for acne vulgaris—not for androgenetic alopecia or hair regrowth. The investigational 5% scalp solution requires its own regulatory review.

Recent reporting describes increased hair density and tolerability over 12 months with the 5% solution. Those findings do not establish permanent regrowth, superiority to existing treatments, or continued benefit after treatment stops.

Can I use clascoterone for hair loss now?

Not as an FDA-approved hair-loss treatment in the United States. A clinician may discuss off-label options, but approval of an acne cream does not validate its use on the scalp.

We recommend avoiding unverified online products and unsupervised use of Winlevi for thinning hair. The concentration, vehicle, delivery, and evidence do not match the investigational scalp product.

If a clinician discusses off-label use, ask which formulation is being prescribed, how it should be applied, what side effects to watch for, and how progress will be measured. Do not assume that a product sold for acne has been tested for scalp hair growth.

Is clascoterone a cure for male pattern hair loss?

No. Androgenetic alopecia is a chronic condition associated with inherited susceptibility and androgen signaling. Clascoterone may eventually help manage it, but calling the treatment a cure goes beyond the available evidence.

Even an effective treatment would generally require ongoing use to maintain its benefit. The available evidence does not yet establish how hair responds after clascoterone is stopped.

How clascoterone may block androgen signaling in scalp follicles

In susceptible follicles, androgen signaling contributes to miniaturization. Hairs gradually become finer and shorter, reducing visible coverage.

Clascoterone competes with androgens at receptors in treated skin. The mechanism is plausible, but mechanism alone cannot prove meaningful cosmetic regrowth.

DHT, androgen receptors, and follicle miniaturization

DHT acts as a signal that binds to androgen receptors. In genetically susceptible scalp areas, that signaling can contribute to progressively smaller follicles. Sensitivity differs between people and across areas of the same scalp.

This is why two people with similar hormone levels can have different patterns of thinning. The diagnosis, distribution of loss, duration, and individual response all matter.

Local receptor blockade versus systemic hormone reduction

Finasteride reduces the conversion of testosterone to DHT. Clascoterone instead aims to block androgen receptors locally.

That local approach may limit systemic exposure, but “topical” does not mean zero absorption or zero risk. Safety must be assessed for the exact concentration, vehicle, dose, and application area.

A scalp product may also behave differently on healthy skin, irritated skin, or skin affected by inflammation. Those details matter when interpreting both efficacy and safety.

What clinical trials actually show about clascoterone 5% solution

What clinical trials actually show about clascoterone 5% solution

The relevant evidence comes from studies of androgenetic alopecia, not acne research or reports involving other skin conditions.

The supplied Dermatology Times source describes phase 3 findings for clascoterone 5% topical solution, including increased hair density and tolerability over 12 months. However, it is an advertisement feature with expert commentary rather than a complete peer-reviewed trial report. We would want full methods and results before drawing firm conclusions.

Evidence Product What it supports What remains uncertain
Male pattern hair-loss research Clascoterone 5% scalp solution Reported improvement in hair density and 12-month tolerability Absolute results, visible cosmetic benefit, durability, attrition, and active-treatment comparisons
Approved acne evidence Clascoterone 1% cream Use for acne vulgaris Scalp dosing, follicular delivery, and hair-regrowth efficacy

How to read the headline percentages

Relative improvements can sound dramatic without showing how much visible hair changed. We look for baseline and final hair counts, vehicle results, standardized photographs, confidence intervals, and patient-reported outcomes.

Without those details, a headline percentage is not enough to judge whether the difference would be noticeable in daily life.

When reading a clascoterone 5% study, also check:

  • Whether the participants had clearly diagnosed androgenetic alopecia
  • Which scalp area was measured
  • Whether results were compared with a vehicle or another treatment
  • How many participants completed the study
  • Whether photographs and hair counts were assessed consistently
  • Whether adverse events and treatment discontinuations were fully reported
  • Whether the study has been published in a peer-reviewed journal

Promising evidence versus proven patient benefit

Hair density or target-area hair count is not the same as satisfaction, easier styling, or visible coverage under normal lighting. Study design, dropouts, adherence, sponsorship, and publication status all affect interpretation.

Cross-trial comparisons are also unreliable when participants, formulations, endpoints, and timelines differ.

A 12-month result can show what happened during that study period. It cannot by itself prove that the result will continue for several years or that treatment will preserve hair after discontinuation.

Winlevi and clascoterone are related—but not interchangeable

Winlevi contains clascoterone in a 1% cream approved for acne. The hair-loss research concerns a 5% scalp solution.

That difference matters. Concentration, vehicle, application area, stability, penetration, and dosing can all influence how a topical drug behaves. Applying Winlevi to thinning areas is not a proven shortcut.

Winlevi is a prescription topical treatment for acne vulgaris. Its labeled acne use involves applying the cream to affected skin, generally twice daily as directed by the prescriber. Those directions should not be transferred to the scalp without specific clinical guidance.

What is acne vulgaris?

Acne vulgaris is an inflammatory skin condition involving blocked pores, oil production, bacteria, and inflammation. Androgen signaling can contribute to oil production, which helps explain clascoterone’s role in acne care.

Male pattern hair loss involves follicle miniaturization and requires separate evidence. An acne medication can target androgen activity in skin without being an effective hair-growth treatment.

Why concentration and vehicle matter

The investigational scalp solution has a higher clascoterone concentration than Winlevi cream, but concentration alone does not reveal the delivered dose or effect.

Inactive ingredients affect spreadability, stability, absorption, irritation, and follicular delivery. Products containing the same active ingredient may therefore perform very differently.

A cream may feel different from a solution and may leave different amounts of product on the scalp. Those practical differences can affect adherence as well as drug delivery.

Can Winlevi moisturize the scalp?

The cream vehicle may affect how the skin feels after application, but any moisturizing or cosmetic effect does not demonstrate hair regrowth. Winlevi should be used for its approved acne indication unless a qualified clinician advises otherwise.

Clascoterone versus finasteride and minoxidil

These treatments use different strategies and should not be reduced to a simple winner-versus-loser comparison.

Treatment Main strategy Hair-loss evidence status
Clascoterone Blocks androgen receptors in treated skin Investigational
Finasteride Reduces DHT production Established
Minoxidil Supports growth through a non-antiandrogen pathway Established

Clascoterone versus finasteride: receptor blockade or DHT reduction

Clascoterone aims to block androgen signaling locally, while finasteride reduces DHT production. A scalp-focused option may appeal to people concerned about systemic treatment, but emerging evidence should not be equated with finasteride’s established evidence base.

Patients considering DHT-reducing medicines can read our comparison of dutasteride versus finasteride and review personal risks with a clinician.

Neither treatment is appropriate for every person. The choice depends on diagnosis, medical history, potential adverse effects, reproductive considerations, treatment preferences, and willingness to continue treatment.

Clascoterone versus minoxidil: antiandrogen action or growth stimulation

Clascoterone targets androgen signaling; minoxidil uses a different pathway. Their distinct mechanisms could support future combination treatment, but this has not established that everyone needs both or that clascoterone will replace minoxidil.

Minoxidil also has its own application instructions, possible irritation, and expectations for continued use. Combining treatments should be based on a clinician’s plan rather than on the assumption that different mechanisms automatically produce better results.

Clascoterone safety: topical does not mean risk-free

Potential topical-drug concerns include redness, itching, burning, dryness, scaling, or sensitivity. The actual risk profile depends on the formulation studied.

Safety findings from a 1% facial cream cannot simply be transferred to long-term use of a 5% scalp solution. Our guide to pre-treatment risk screening explains why route, health history, and application area matter.

The approved acne product also carries product-specific safety information. That information can help explain known reactions to the 1% cream, but it is not a substitute for safety data on an investigational 5% scalp formulation.

What lower systemic exposure can—and cannot—tell us

Lower systemic exposure may reduce some risks, but it does not prove that absorption is zero. Concentration, vehicle, skin condition, application area, and frequency can all affect exposure.

Avoid applying a topical drug to broken or severely irritated skin unless a clinician specifically instructs you to do so. Tell your clinician about other scalp products and medicines, especially if irritation develops after combining treatments.

Questions that longer studies still need to answer

We still need clear information about:

  • Benefit during continued use
  • Results after treatment stops
  • Rare adverse effects
  • Long-term scalp tolerability
  • Real-world adherence
  • Safety across broader patient groups
  • Whether benefits differ by sex, age, ethnicity, or pattern of loss
  • How clascoterone performs against established treatments

Complete publications are essential. Topline reports cannot replace adverse-event data, dropout explanations, and peer-reviewed methods.

Stop using a topical product and seek medical advice if you develop severe irritation, swelling, blistering, signs of infection, or symptoms that concern you. A clinician can determine whether the reaction is from the product, another scalp condition, or a separate cause.

Is clascoterone FDA-approved for hair loss, and where can you buy it?

As of the review date above, clascoterone is not FDA-approved for androgenetic alopecia. Winlevi’s acne approval does not extend to a different concentration, vehicle, body site, or indication.

In practical terms, there is no FDA-approved clascoterone hair-loss product that consumers can obtain as a standard treatment for androgenetic alopecia in the United States. Availability through a website, clinic, or compounding pharmacy does not change that regulatory status.

Approval, off-label use, and clinical trials are different

  • Approved use: A regulator has reviewed a specific product for a defined indication.
  • Off-label use: A clinician prescribes an approved product outside its label.
  • Clinical-trial access: Participants receive an investigational treatment under a study protocol.
  • Compounded access: A pharmacy prepares a customized product; this does not equal FDA approval of that formulation.

A clinician may legally prescribe an approved medicine off label in some circumstances, but the patient should understand that the evidence, instructions, and safety data may not match the proposed use.

Why “buy clascoterone online” is a risky shortcut

An unverified product may have uncertain ingredients, concentration, stability, storage, or contamination controls. Buying without clinical oversight also removes diagnosis, contraindication screening, baseline assessment, and monitoring. We do not recommend self-dosing with online products.

Do not assume that a listing for “clascoterone 5%” is the same product studied in a clinical trial. The source, formulation, quality controls, and instructions all need verification.

Should you wait for clascoterone or treat hair loss now?

Waiting does not pause follicle miniaturization. We recommend assessment while established options can still be considered.

A clinician can distinguish androgenetic alopecia from shedding disorders, scalp inflammation, medication effects, nutritional problems, or scarring conditions. Progress can then be tracked with consistent photographs, adherence records, and side-effect monitoring.

Signs that call for a clinician assessment now

Seek assessment for sudden shedding, patchy loss, scalp pain, persistent redness, heavy scaling, scar-like areas, or rapidly progressing changes. These features may point to a condition other than straightforward pattern hair loss.

A diagnosis is especially important when hair loss begins abruptly, follows an illness or major stressor, affects the eyebrows or body, or occurs with changes in the scalp.

A practical decision framework

We ask whether the diagnosis is clear, whether loss is progressing, which established treatments have been considered, and whether cost, risk, monitoring, and treatment burden are acceptable. Evidence must also match the proposed concentration and formulation.

Before considering an investigational or off-label product, ask:

  1. What is the most likely cause of the hair loss?
  2. What evidence supports this exact product and concentration?
  3. What established treatments are available now?
  4. What side effects and interactions should be monitored?
  5. How will improvement or worsening be measured?
  6. What is the plan if the treatment does not work?

Where clascoterone could fit in personalized hair-loss care

If clascoterone gains formulation-specific authorization and stronger published support, it may become one component of a monitored plan rather than a universal replacement for finasteride or minoxidil.

Its potential role may be most relevant for people who want a topical antiandrogen approach, cannot tolerate an established treatment, or need a treatment plan tailored to their medical history. Those possible roles remain hypothetical until the formulation has appropriate regulatory review and supporting evidence.

What genetics can contribute

Genetic information may add context about inherited susceptibility. It works best alongside medical history, scalp examination, progression, and treatment response.

Our guide to what a genetic test for hair loss can—and cannot—tell you explains how we use DNA as one input rather than a standalone prescription tool.

What genetics cannot yet predict

A consumer genetic marker cannot guarantee that clascoterone will work or remain free of side effects. Genetics also cannot select a proven clascoterone dose or vehicle for an individual.

Treatment decisions still require a clinical diagnosis and a realistic assessment of benefits, risks, cost, and follow-up.

FAQ

Can I use clascoterone for hair loss?

Clascoterone is not currently FDA-approved for hair loss. We recommend discussing approved treatments and any proposed off-label use with a licensed clinician.

Is Winlevi clascoterone?

Yes. Winlevi is a 1% clascoterone cream for acne, but it is not interchangeable with the investigational 5% scalp solution.

Is Winlevi appropriate for hair loss?

Winlevi is approved for acne vulgaris, not androgenetic alopecia or hair regrowth. A clinician may discuss off-label options, but you should not assume that using Winlevi on the scalp has been proven safe or effective for hair loss.

Does clascoterone cream regrow hair?

Evidence supporting Winlevi for acne does not prove that the cream regrows scalp hair. The hair-loss research uses a different concentration and formulation.

How often is Winlevi used?

Winlevi’s acne directions involve topical application twice daily as prescribed. Those directions are for acne and should not be copied for scalp hair loss without medical guidance.

What are the possible side effects of Winlevi cream?

Possible topical reactions include redness, itching, burning, dryness, scaling, or sensitivity. Follow the product’s prescribing information and contact a clinician about severe, persistent, or concerning reactions.

The safety profile of Winlevi 1% cream also cannot be assumed to predict the safety of an investigational clascoterone 5% scalp solution.

Is clascoterone safer than finasteride?

The available evidence does not support a blanket claim that one is safer. Route, dose, formulation, medical history, and the specific adverse effect being considered all matter.

Is clascoterone available as a hair-loss tablet?

There is no established clascoterone tablet for hair loss. The current hair-loss research concerns a topical scalp formulation.

Is clascoterone a DHT blocker?

Clascoterone is designed to block androgen receptors in treated skin. It is not the same as finasteride, which reduces DHT production by inhibiting the conversion of testosterone to DHT.

Build a plan around your biology

Do not put established care on hold for an investigational treatment. Explore a personalized hair-loss plan with rootsbyga.com based on biology, progression, tolerance, and measurable results.

Roots by Genetic Arts

21 Oct 2026

Resume Subscription

Your subscription is on hold because the last payment failed.
Would you like to renew your subscription and process the payment now?